Insights

Strategic Oncology Healx is actively expanding into oncology through strategic partnerships with Vuja De Sciences to prevent cancer recurrence and metastatic endurance, presenting an opportunity to offer AI-driven drug discovery collaborations or data-sharing arrangements to accelerate oncology programs.

Neuro & SCI The 2025 partnership with SCI Ventures targets spinal cord injury therapies, indicating appetite for AI-enabled discovery in neurodegenerative and paralytic conditions, creating potential sales angles around platform access, collaboration models, and medicinal chemistry support.

Rare Disease Focus Healx concentrates on rare diseases with a large unmet need; with 400 million affected globally and only a fraction with approved treatments, there is strong demand for expanded AI-driven screening, target identification, and clinical development services.

Leadership & Funding Recent leadership appointments and a substantial funding round (lead investors Atomico and R42 in 2024) signal a growth trajectory and willingness to partner on large, multi-year AI drug discovery programs across rare indications.

Sanofi Collaboration Existing Sanofi collaboration to repurpose a discontinued asset using Healx’s AI points to open channels for additional licensing, co-development, or data partnerships with large pharma seeking accelerated rare-disease asset proliferation.

Similar companies to Healx

Healx Tech Stack

Healx uses 8 technology products and services including Docker, WordPress, Mimecast, and more. Explore Healx's tech stack below.

Media & News

Healx's Email Address Formats

Healx uses at least 6 email formats:
Healx Email FormatsExamplePercentage
First.Last@healx.ioJohn.Doe@healx.io
91%
First@healx.ioJohn@healx.io
4%
First.Middle@healx.ioJohn.Michael@healx.io
4%
Last@healx.ioDoe@healx.io
1%
First.Middle@healx.aiJohn.Michael@healx.ai
50%
First.Last@healx.aiJohn.Doe@healx.ai
50%

Frequently Asked Questions

What is Healx's official website and social media links?

Minus sign iconPlus sign icon
Healx's official website is healx.ai and has social profiles on LinkedIn and Crunchbase.

How much revenue does Healx generate?

Minus sign iconPlus sign icon
As of October 2026, Healx's annual revenue is estimated to be $1M - $10M.

What is Healx's SIC code and NAICS code?

Minus sign iconPlus sign icon
Healx's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Healx have currently?

Minus sign iconPlus sign icon
As of October 2026, Healx has approximately 70 employees across 4 continents, including Europe, North America and Asia. Key team members include Cto: M. W., Chief Operating Officer: K. H. and Head Of Operations People And Technician: N. S. Explore Healx's employee directory with LeadIQ.

What industry does Healx belong to?

Minus sign iconPlus sign icon
Healx operates in the Biotechnology Research industry.

What technology does Healx use?

Minus sign iconPlus sign icon
Healx's tech stack includes Docker, WordPress, Mimecast, Jamf, DocuSign, BambooHR, Greenhouse and Wrike.

What is Healx's email format?

Minus sign iconPlus sign icon
Healx's email format typically follows the pattern of First.Last@healx.io. Find more Healx email formats with LeadIQ.

How much funding has Healx raised to date?

Minus sign iconPlus sign icon
As of October 2026, Healx has raised $115M in funding. The last funding round occurred on Jul 01, 2025.

When was Healx founded?

Minus sign iconPlus sign icon
Healx was founded in 2014.
Healx logo

Healx

Biotechnology ResearchEngland, United Kingdom51-200 Employees

Healx is a biotechnology research company based in Cambridge, East of England. It focuses on AI-enabled drug discovery to bring novel therapies to people with rare diseases. By integrating artificial intelligence with established drug discovery and development expertise, it aims to accelerate programs, broaden the scope of conditions considered, and improve the likelihood of success in rare-disease initiatives. The company notes that more than 10,000 rare diseases affect about 400 million people worldwide.

Healx engages with external partners to apply its AI-driven approach to rare-disease programs. A notable development in 2024 was a collaboration with Sanofi Synthelabo Ltd to identify rare-disease indications for a discontinued asset. Public descriptions characterize Healx as a clinical-stage biotechnology company focused on rare diseases and operating with a mid-sized workforce.

Section iconCompany Overview

Website
healx.ai
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2014
Employees
51-200

Section iconFunding & Financials

  • $115M

    Healx has raised a total of $115M of funding over 8 rounds. Their latest funding round was raised on Jul 01, 2025 as a Venture Round.

  • $1M - $10M

    Healx's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.